← Back to Search

Unknown

CIN-107 for High blood pressure (HALO Trial)

Phase 2

Waitlist Available

Research Sponsored by CinCor Pharma, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 8 weeks

Summary

This trial is testing a new medication called baxdrostat to see if it can help people with high blood pressure that isn't controlled by their current treatment. The medication aims to lower blood pressure by relaxing and widening blood vessels. People will take the medication for a few weeks to see if it helps.

Eligible Conditions

High blood pressure

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 8 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~8 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change From Baseline in Mean Seated Systolic BP (SBP)

Secondary study objectives

Change From Baseline in 24-hour Serum Aldosterone

Change From Baseline in 24-hour Serum Renin

Change From Baseline in 24-hour Urine Aldosterone

+3 more

Side effects data

From 2022 Phase 2 trial • 275 Patients • NCT04519658

Urinary tract infection

Hyperkalaemia

Headache

100%

80%

60%

40%

20%

Study treatment Arm

Safety Population 0.5mg

Safety Population Placebo

Safety Population 1mg

Safety Population 2mg

Trial Design

4Treatment groups

Experimental Treatment

Placebo Group

Group I: CIN-107 2 mgExperimental Treatment1 Intervention

Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient may remain on CIN-107 (2 mg) and discontinue their background antihypertensive agent(s) for 4 weeks or withdraw study participation depending on BP control

Group II: CIN-107 1 mgExperimental Treatment1 Intervention

Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient will receive the highest dose of CIN-107 (2 mg) and discontinue their background antihypertensive agent(s) for 4 weeks

Group III: CIN-107 0.5 mgExperimental Treatment1 Intervention

Group IV: PlaceboPlacebo Group1 Intervention

Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient will receive the highest dose of CIN-107 (2mg) and discontinue their background antihypertensive agent(s) for 4 weeks

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

CIN-107

2022

Completed Phase 2

~1010

Do I qualify?Apply below to find out